or avNRS among the 3 arms ( Table 1 ). Other baseline characteristics were well balanced between the 3 groups, with comparable ESAS symptom severity ( supplemental eTable 2 and Table 1 ). Figure 1. Study profile. (A1) Bolus-only arm, (A2
Search Results
Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial
Rongbo Lin, Jinfeng Zhu, Yushuang Luo, Xia Lv, Mingqian Lu, Haihui Chen, Huichao Zou, Zhichun Zhang, Shaowei Lin, Milu Wu, Xiaofeng Li, Min Zhou, Shen Zhao, Liyu Su, Jiang Liu, and Cheng Huang
Neuroendocrine Tumors
Matthew H. Kulke, Al B. Benson III, Emily Bergsland, Jordan D. Berlin, Lawrence S. Blaszkowsky, Michael A. Choti, Orlo H. Clark, Gerard M. Doherty, James Eason, Lyska Emerson, Paul F. Engstrom, Whitney S. Goldner, Martin J. Heslin, Fouad Kandeel, Pamela L. Kunz, Boris W. Kuvshinoff II, Jeffrey F. Moley, Venu G. Pillarisetty, Leonard Saltz, David E. Schteingart, Manisha H. Shah, Stephen Shibata, Jonathan R. Strosberg, Jean-Nicolas Vauthey, Rebekah White, James C. Yao, Deborah A. Freedman-Cass, and Mary A. Dwyer
< 5% of patients) are not specifically discussed in these guidelines. Histologic Classification and Staging of Neuroendocrine Tumors Neuroendocrine tumors are generally subclassified by site of origin and histologic characteristics. Pancreatic
Impact of Facility Surgical Volume on Survival in Patients With Cancer
Kelsey C. Stoltzfus, Biyi Shen, Leila Tchelebi, Daniel M. Trifiletti, Niraj J. Gusani, Vonn Walter, Ming Wang, and Nicholas G. Zaorsky
insurance (51.6%), and had stage 0–III disease (64.8%). Patients traveled an average of 30.9 miles to get to their treatment facility. These results are summarized in Table 1 . Table 1. Patient Characteristics Surgical facility volume
Comparison of Cancer Burden and Nonprofit Organization Funding Reveals Disparities in Funding Across Cancer Types
Suneel D. Kamath, Sheetal M. Kircher, and Al B. Benson III
amount of annual revenue supporting each cancer type. Table 1. Characteristics of Nonprofit Organizations Among cancer type–specific NPOs, the cancers with the largest number of organizations were breast cancer (13; 22%), pediatric cancers (13; 22
Nonoperative Treatment of Large (5–7 cm), Node-Negative Non–Small Cell Lung Cancer Commonly Deviates From NCCN Guidelines
Craig S. Schneider, Robert A. Oster, Aparna Hegde, Michael C. Dobelbower, John M. Stahl, and Adam J. Kole
chemotherapy. Most patients received CFRT (64.3%), whereas SBRT (21.8%) and HFRT (13.9%) were less common. The most commonly used RT fractionation regimen for each category can be found in supplemental eTable 1 . Table 1. Patient Characteristics
Carcinoma in situ of the Urinary Bladder: Review of Clinicopathologic Characteristics with an Emphasis on Aspects Related to Molecular Diagnostic Techniques and Prognosis
Nalan Nese, Ruta Gupta, Matthew H. T. Bui, and Mahul B. Amin
Edited by Kerrin G. Robinson
Carcinoma in situ (CIS) of the urinary bladder is defined as a flat lesion comprising of cytologically malignant cells which may involve either full or partial thickness of the urothelium. De novo CIS constitutes less than 3% of all urothelial neoplasms; however, CIS detected concurrently or secondarily during follow-up of urothelial carcinoma constitutes 45% and 90%, respectively, of bladder cancer. CIS is noted predominantly in male smokers in the sixth or seventh decade. Patients may present with dysuria, nocturia, and urinary frequency and urgency with microscopic hematuria. Cystoscopic findings may range from unremarkable to erythema or edema. Urine cytology is an important diagnostic tool. Cellular anaplasia, loss of polarity, discohesion, nuclear enlargement, hyperchromasia, pleomorphism, and atypical mitoses are the histopathologic hallmarks of CIS. Extensive denud ation of the urothelium, monomorphic appearance of the neoplastic cells, inflammatory atypia, radiation induced nuclear smudging, multinucleation, and pagetoid spread of CIS may cause diagnostic difficulties. Together with clinical and morphologic correlation, immunostaining with CK 20, p53 (full thickness), and CD44 (absence of staining) may help accurately diagnose CIS. Fluorescent in situ hybridization analysis of voided urine for amplification of chromosomes 3, 7, and 17 and deletion of 9p has high sensitivity and specificity for diagnosing CIS in surveillance cases. Several other molecular markers, such as NMP 22 and BTA, are under evaluation or used variably in clinical pathology. Intravesical bacillus Calmette-Guerin (BCG) instillation is considered the preferred treatment, with radical cystectomy being offered to refractory cases. Chemotherapy, α-interferon, and photodynamic therapy are other modalities that can be considered in BCG-refractory cases. Multifocality, involvement of prostatic urethra, and response to BCG remain the most important prognostic factors, although newer molecular markers are being evaluated for this entity. Patient outcome varies based on whether it is de novo development or diagnosed secondary to prior or concomitant papillary bladder cancer. From a clinical perspective, the principal determinants of outcome are extent of disease, involvement of prostatic urethra, response to therapy, and time to recurrence.
HSR23-114: Clinical Characteristics and Outcomes of US Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients Not Receiving Guideline Preferred Regimens
Daniel Simmons, Yang Xiao, Corina Roca, Zhuoxin Jiang, and Marnie Boron
CLO21-018: Clinical Characteristics of Breast Cancer Patients Treated With Trastuzumab-anns, a Trastuzumab Biosimilar, in a Real-World Setting
Ran Jin, Neil Accortt, Darcie Sandschafer, Tatiana Lawrence, and Reshma Mahtani
Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis
Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang
knowledge regarding the typical characteristics of ICI-related esophagitis and the appropriate treatments for this condition. In this retrospective study, we aimed to characterize esophagitis associated with the use of ICIs and describe its clinical
HSR22-153: Real-World Time to Discontinuation of First-Line Venetoclax + Obinutuzumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Xiaoxiao Lu, Qing Huang, Linda Wu, Bruno Emond, Shaun P. Forbes, Annalise Hilts, Stephanie Liu, Marie-Hélène Lafeuille, Patrick Lefebvre, and Kerry A. Rogers
evaluated time to discontinuation (TTD) and characteristics associated with TTD for first-line (1L) V+G. Methods : The nationwide Flatiron Health electronic health record-derived de-identified database (4/11/15-6/30/21) was used to select adults with CLL
